The majority of patients (n = 33, 89.2%) had INSS stage 4 (M) neuroblastoma at diagnosis, and four (10.8%) had INSS stage 3 (L2) disease with MYCN amplification. The gene discussed is MYCN; the disease is neuroblastoma.